Biolex Therapeutics names Kurt Graves Executive Chairman

The Board of Directors of Biolex Therapeutics, Inc. today announced the appointment of Kurt Graves as Executive Chairman of the Board. In this newly created position, Mr. Graves will provide strategic leadership to the Board and work closely with executive management as the Company advances its potential blockbuster Locteron(R), a next-generation interferon for hepatitis C (HCV), into late-stage development and prepares for strategic partnering and selection of commercialization alternatives for the product.